CURE Pharmaceutical Completes Going Public Transaction

CURE Pharmaceutical (OTC Pink:CURR), a preeminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, announces today the completion of a going public transaction and the issuance of its new stock symbol – CURR.
Headquartered in Oxnard, CA, CURE Pharmaceutical has developed and manufactures the most advanced oral thin film (CureFilm™) on the market today supported by its in-house, industry-leading full service cGMP manufacturing facility. CureFilm is more stable and durable than other oral thin films, with the ability to augment the dissolution for the intended rate of release through the bucal or gastrointestinal system. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance, through its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lowering dosing, and enhancing, efficacy thereby widening the therapeutic index.
Forward-looking statementsThis press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company’s business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.Contact:
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com